Illumina (NASDAQ:ILMN) Reaches New 52-Week High – Still a Buy?

Illumina, Inc. (NASDAQ:ILMN)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $195.09 and last traded at $194.33, with a volume of 2102097 shares traded. The stock had previously closed at $188.68.

Analyst Ratings Changes

Several brokerages have issued reports on ILMN. Piper Sandler upped their target price on Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Thursday, May 14th. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Sanford C. Bernstein started coverage on shares of Illumina in a report on Friday, June 26th. They set a “market perform” rating and a $185.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $148.94.

Illumina Price Performance

The company has a market capitalization of $29.40 billion, a PE ratio of 35.33, a PEG ratio of 3.53 and a beta of 1.47. The firm has a fifty day moving average of $154.74 and a two-hundred day moving average of $139.45. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts anticipate that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC boosted its position in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Illumina in the 2nd quarter worth about $621,000. CW Advisors LLC purchased a new position in Illumina in the second quarter worth about $275,000. Marshall Wace LLP lifted its position in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC lifted its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.